Gemlapodect

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Gemlapodect ( , ; developmental code name NOE-105) is a phosphodiesterase PDE10A inhibitor which is under development for the treatment of Tourette's syndrome and speech disorders. It is taken orally. The drug is thought to work by modulating dopaminergic signaling in the striatum through PDE10A inhibition in medium spiny neurons. Gemlapodect was originated by Roche and is under development by Noema Pharma. As of September 2025, it is in phase 2 clinical trials for both Tourette's syndrome and speech disorders.

Gemlapodect ( , ; developmental code name NOE-105) is a phosphodiesterase PDE10A inhibitor which is under development for the treatment of Tourette's syndrome and speech disorders. It is taken orally. The drug is thought to work by modulating dopaminergic signaling in the striatum through PDE10A inhibition in medium spiny neurons. Gemlapodect was originated by Roche and is under development by Noema Pharma. As of September 2025, it is in phase 2 clinical trials for both Tourette's syndrome and speech disorders.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1357722988 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.